Ebola Vaccine Shows Promise Against Deadly Bundibugyo Virus

An existing Ebola vaccine is showing promising signs that it might protect against a deadly virus outbreak currently spreading through the Democratic Republic of Congo.

The World Health Organization announced Thursday that Ervebo, a licensed Ebola vaccine, will enter Phase III human trials to test whether it can defend against Bundibugyo virus disease. Animal studies have already shown encouraging results that the vaccine provides cross-protection against this virus strain.

WHO Director-General Tedros Ghebreyesus shared that two vaccines specifically designed for Bundibugyo virus have also entered early safety trials in humans. The multi-pronged approach reflects the urgency of the situation as the outbreak continues to spread.

The current outbreak in the DRC has become the second-largest Ebola outbreak on record, with 4,449 confirmed cases and 2,061 deaths across five provinces. The virus was first detected in May after health officials investigated an unexplained cluster of deaths in Ituri Province.

This outbreak is spreading faster than any previous Ebola outbreak at the same stage. Uganda has also confirmed imported cases linked to the DRC outbreak, prompting WHO to declare a Public Health Emergency of International Concern.

Why This Inspires

The speed of the scientific response shows how much global health coordination has improved since previous outbreaks. Researchers mobilized quickly to explore whether existing tools could be repurposed, rather than starting from scratch.

A WHO-sponsored treatment trial has already enrolled 100 patients, testing therapies that could improve outcomes for infected people. Ghebreyesus emphasized that reaching this milestone proves research can move forward rapidly and responsibly even during difficult outbreaks.

Previous Bundibugyo virus outbreaks have had fatality rates between 30 and 50 percent, making the development of effective vaccines and treatments crucial. Unlike the more common Ebola virus, no licensed vaccine currently exists specifically for Bundibugyo virus disease.

The collaboration involves the DRC government, WHO, Africa Centres for Disease Control and Prevention, and multiple research partners working together. Their combined efforts aim to fast-track solutions that could save lives in this outbreak and prevent future ones.

Scientists hope to begin the Phase III vaccine trial as soon as possible to determine whether Ervebo is both safe and effective against Bundibugyo virus in humans. The evidence gathered could make the vaccine available for immediate use and stockpiling for future outbreaks.